4D Molecular Therapeutics Inc (FDMT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $9.66
• Market Cap: $566.78M
• EPS: $-3.75
• 52-Week High: $12.34
• 52-Week Low: $2.23

Market Sentiment

4D Molecular Therapeutics Inc currently has a Bullish sentiment score of 0.33.

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Emeryville, California, dedicated to pioneering advanced therapeutics using its proprietary adeno-associated virus (AAV) vector platform. The company is at the forefront of addressing critical unmet medical needs in ophthalmology, neurology, and rare diseases, with a strong focus on transforming patient outcomes through innovative gene therapies. With a well-developed pipeline and strategic collaboration...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for 4D Molecular Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does FDMT pay dividends?

4D Molecular Therapeutics Inc (FDMT) does not currently pay a regular dividend.

What is FDMT's market cap?

4D Molecular Therapeutics Inc (FDMT) has a market capitalization of $566.78M with a current stock price of $9.66.